| SC 13G/A | 2024-02-14 | Lynx1 Capital Management LP | Neurogene Inc. | 46 | - | EDGAR |
| SC 13G/A | 2024-02-14 | Redmile Group, LLC | Neurogene Inc. | 1,050,304 | 8.1% | EDGAR |
| SC 13G/A | 2024-02-14 | GREAT POINT PARTNERS LLC | Neurogene Inc. | 994,229 | 7.8% | EDGAR |
| SC 13G | 2024-02-14 | Cormorant Asset Management, LP | Neurogene Inc. | 155,805 | - | EDGAR |
| SC 13G | 2024-02-14 | EcoR1 Capital, LLC | Neurogene Inc. | 1,282,168 | 10.0% | EDGAR |
| SC 13G | 2024-02-14 | Samsara BioCapital, L.P. | Neurogene Inc. | 1,282,563 | 10.0% | EDGAR |
| SC 13G | 2024-02-14 | JANUS HENDERSON GROUP PLC | Neurogene Inc. | 841,688 | 6.6% | EDGAR |
| SC 13G | 2023-12-27 | GREAT POINT PARTNERS LLC | Neurogene Inc. | 969,229 | 7.6% | EDGAR |
| SC 13G/A | 2023-12-22 | Redmile Group, LLC | Neurogene Inc. | 1,282,661 | 9.9% | EDGAR |
| SC 13D | 2023-12-21 | McMinn Rachel | Neurogene Inc. | 1,273,351 | 9.9% | EDGAR |
| SC 13D/A | 2023-12-20 | BAKER BROS. ADVISORS LP | Neurogene Inc. | 649,572 | 5.0% | EDGAR |
| SC 13D/A | 2023-10-10 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 1,894,217 | 20.0% | EDGAR |
| SC 13D/A | 2023-08-17 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 9,469,838 | 20.0% | EDGAR |
| SC 13D | 2023-07-27 | Redmile Group, LLC | Neoleukin Therapeutics, Inc. | 2,912,228 | 6.6% | EDGAR |
| SC 13D/A | 2023-07-19 | BAKER BROS. ADVISORS LP | Neoleukin Therapeutics, Inc. | 10,040,817 | 20.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Redmile Group, LLC | Neoleukin Therapeutics, Inc. | 3,030,566 | 6.9% | EDGAR |
| SC 13G | 2023-02-03 | PICTET ASSET MANAGEMENT SA | Neoleukin Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-01-19 | MILLENNIUM MANAGEMENT LLC | Neoleukin Therapeutics, Inc. | 1,587,267 | 3.7% | EDGAR |
| SC 13G | 2022-12-30 | Lynx1 Capital Management LP | Neoleukin Therapeutics, Inc. | 2,291,133 | 5.4% | EDGAR |
| SC 13G | 2022-07-19 | MILLENNIUM MANAGEMENT LLC | Neoleukin Therapeutics, Inc. | 2,132,586 | 5.0% | EDGAR |